Compare Noble Corporation plc (NE) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Noble Corporation plc trades at $42.9 (market cap $6.85B), while Spyre Therapeutics Inc. Common Stock trades at $78.4 (market cap $7.35B). The key difference: Noble Corporation plc and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and Noble Corporation plc pays a 4.66% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Noble Corporation plc for 27 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NE | SYRE | |
|---|---|---|
Market Cap | $6.85B | $7.35B |
Volume | 984,361 | 1,624,631 |
Sector | Energy | Health |
52-Week High | $54.37 | $108.92 |
52-Week Low | $27.45 | $22.18 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | $8.28B | $6.35B |
Dividend Yield | 4.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $43.42, up 1.12% today. The stock shows mixed signals with a bullish technical outlook but bearish moving averages. Recent earnings have been volatile, with Q1 2026 beating expectations but Q2 and Q4 2025 missing. Revenue declined from $3.3B in 2025 to $3.1B in 2026, and net income fell from $217M to $150M. Positive news includes a long-term drilling contract in Ghana, but the company faces an ongoing law firm investigation.
Outlook is cautious. The consensus price target of $52.00 implies potential upside, supported by a 'Buy' rating from 31% of analysts. However, declining profitability, mixed earnings history, and legal scrutiny present risks. Investors should weigh contract wins against fundamental pressures and sentiment headwinds.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
